The Asia-Pacific (APAC) region is witnessing a substantial shift in biopharma innovation, manufacturing, and outsourcing, driven primarily by China’s burgeoning biopharma sector. CPHI Japan 2023, scheduled for April 19-21, provides the perfect setting for industry experts to delve into the extensive ramifications of China’s rapidly expanding influence on the region. Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, is set to discuss the impact of China’s booming biopharma industry on the APAC region during his keynote address.
The event, marking its 20th anniversary, will feature a range of special events, including an award ceremony recognizing companies that have played a pivotal role in shaping Japan’s flourishing pharmaceutical sector. With an anticipated attendance of 7,000 executives from 95 countries, CPHI Japan 2023 signals a return to pre-pandemic levels of engagement.
As China’s share of global R&D in new drugs and vaccines climbs to 24%, the country’s growing influence on the APAC region’s biopharma landscape is undeniable. This shift is leading to the emergence of innovative distribution channels and regional manufacturing hubs, particularly in Southeast Asia and Japan, which are now being targeted by China due to recent challenges in the US market.
Japan’s innovation scene remains strong, with stable growth, but drug pricing systems continue to present challenges for research-based multinationals operating in the country. The diverse group of smaller innovators in the APAC biopharma sector fosters a dynamic and varied supply side, teeming with a multitude of supply partners.
